Cargando...
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques composed mainly of amyloid-β (Aβ) protein. Overproduction or slow clearance of Aβ initiates a cascade of pathologic events that may lead to formation of neurofibrillary tangles, neuronal cell death, and dementia. Although i...
Gardado en:
| Publicado en: | Immunotargets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918231/ https://ncbi.nlm.nih.gov/pubmed/27471697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40131 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|